Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19 Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19
A cluster of cases of diabetic ketoacidosis in which there was no hyperglycemia supports recommendations that SGLT2 inhibitors be discontinued in patients with type 2 diabetes who become ill with COVID-19.Medscape Medical News
Source: Medscape Emergency Medicine Headlines - Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news
More News: COVID-19 | Diabetes | Diabetes Type 2 | Emergency Medicine | Endocrinology | Infectious Diseases | SGLT2 Inhibitors | Warnings